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Abstract
Background: Surrogate pain models have been extensively tested in Normal Human Volunteers (NHV). There are
few studies that examined pain models in chronic pain patients. Patients are likely to have altered pain mechanisms.
It is of interest to test patient pain responses to selective pain stimuli under controlled laboratory conditions.
Methods: The Institutional Ethic Committee approved the study. 16 patients with chronic neuropathic
radiculopathy and 16 healthy volunteers were enrolled to the study after obtaining informed consent. During
electrical stimulation (150 minutes for volunteers and 75 minutes for patients) the following parameters were
measured every 10 minutes:
Ongoing pain: Visual Analogue Scale (VAS) and Numeric Rate Scale (NRS)
Allodynia (soft foam brush)
Hyperalgesia (von Frey monofilament 20 g)
Flare
For each endpoint, the area under the curve (AUC) was estimated from the start of stimulation to the end of sti-
mulation by the trapezoidal rule. The individual AUC values for both periods were plotted to show the inter- and
intra-subject variability. For each endpoint a mixed effect model was fitted with random effect subject and fixed
effect visit. The estimate of intra-subject variance and the mean value were then used to estimate the sample size
of a crossover study required to have a probability of 0.80 to detect a 25% change in the mean value. Analysis was
done using GenStat 8
th edition.
Results: Each endpoint achieved very good reproducibility for patients and NHV. Comparison between groups
revealed trends towards:
Faster habituation to painful stimuli in patients
Bigger areas of hyperalgesia in patients
Similar area of allodynia and flare (no statistical significance)
Conclusion: The differences demonstrated between patients and NHVs suggest that the electrical stimulation
device used here may stimulate pathways that are affected in the pathological state.
Background
Experimental pain models are key tools for improving
our understanding of pain mechanisms and play an
increasingly important role in providing early evidence
of clinical efficacy, evaluating new analgesic compounds
and establishing a link between preclinical and clinical
pain research. Assessment of clinical pain presents a
unique challenge compared to other major health condi-
tions, such as heart disease or cancer, which can be
detected by objective biological measurements, where
the diagnosis of chronic pain depends upon subjective
reports by patients on the presence and intensity of
pain. However, comparable reports on sensory attributes
cannot be obtained from laboratory animals without
language skills [1]. * Correspondence: magdihanna6262@aol.com
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field of pain research was highlighted recently following
the development of the ‘selective substance P receptor
antagonist class’ which was efficacious in a wide range of
animal models, but failed to alleviate pain in patients
[2,3]. Ultimately, only patient studies can truly validate
the clinical efficacy of new analgesics, however these clin-
ical trials are very expensive for early phase drug evalua-
tion. Surrogate or experimental pain models in human
volunteers represent a more economical approach than
patient clinical trials, as they require a smaller number of
subjects and are therefore less expensive. This is achieved
whilst maintaining good experimental control of the
model itself. Nonetheless, surrogate pain models have
suffered from a lack of reproducible data and inconsis-
tency of pharmacological characterization.
The ultimate goal of modern pain assessment is to
obtain a better understanding of mechanisms involved in
pain transduction, transmission and perception under nor-
mal and pathophysiological conditions [4]. Surrogate
human pain models should use standardized methodology
to produce reproducible endpoints. Methodology should
be appropriate and ethical for both patients and
volunteers.
There is a long and well-documented history of elec-
trically induced pain, sensitization and flare [5-9].
Nevertheless, there are a number of barriers that limit
the wider application of electrical pain models in pain
research. Earlier methods utilized an “almost unbearable
intensity” of current [6,9]. The introduction of intra-der-
mal stimulation led to a reduction in the intensity of
pain needed to evoke sensitization but required invasive
procedures. This included drilling an epidermal hole [5],
inserting custom made intradermal needles [8] or insert-
ing sterile custom made intradermal electrodes [7].
Intradermal electric pain models [8] are able to produce
ongoing pain, hyperalgesia and flare in reproducible pat-
terns. Intradermal electrical pain model was character-
ized by many pharmacological agents including:
intravenous alfentanil, S(+)-ketamine, lidocaine [8], tra-
madol and acetaminophen [10], Pregabalin and Aprepi-
tant [11]. Additionally this model was extensively used
to investigate mechanisms of hyperalgesia [12-17]. The
use of intradermal electrodes that need to be inserted
under ice analgesia could limit the wider use of this
m o d e l .T h ei n v a s i v en a t u r eo ft h ep r o c e d u r ei sl i k e l yt o
exclude utilizing this model in chronic pain patients on
practical and ethical grounds. The Transdermal Electric
Stimulation (TDES), where it is free from skin insertion,
is the next step in the development of electric pain
models. The new model would offer a safer testing of
patients as well as healthy volunteers.
Neuropathic patients are already suffered from altered
pathways and central sensitization. Our hypothesis is
that the sympathology may be localized in some area or
another. Global central sensitization is likely to produce
abnormalities anyway within central nervous system
which had never been explored before
The aims of this study were 1) to evaluate reproduci-
bility, safety and tolerability of pain and sensitization
produced by TDES in (a) patients with chronic lumbo-
sacral pain with radicular neuropathic features and (b)
Normal Healthy Volunteers (NHV) and 2) compare the
differences in the pain endpoints of hyperalgesia and
allodynia between those two groups.
Methods
Study protocol
Two experiments one on patients and the other on
NHV with similar experimental paradigm was per-
formed. Each of them consisted of two identical ses-
sions, at least one week apart, and was conducted to
assess reproducibility and tolerability of TDES. 16
healthy volunteers were recruited for the first experi-
ment and 16 patients suffering from lumbosacral pain
with radicular neuropathic features were recruited for
the second experiment. Subjects were seated comforta-
bly in a reclining chair, with the forearms resting with
the volar side up. Room temperature was controlled at
20 - 24 degree Celsius. The same investigator performed
both sessions for each subject. The assessments for the
N H V ss t u d yw e r ep e r f o r m e db yas i n g l ei n v e s t i g a t o r
(investigator 1); whereas the assessments for the patients
study were performed by two different investigators:
investigator 1 (same as for the NHVs study) assessed
patients ID01 to ID06, ID13 and ID14, and investigator
2 assessed patients ID7 to ID12.
Volunteers
After approval from the Institutional Ethic Committee
16 male NHVs (mean age: 27.8 years, range 22-38) were
recruited and 16 male patients (mean age: 42.6 years,
range: 39-66) diagnosed with chronic lumbosacral pain
with radicular neuropathic features were recruited. If
English was not the subjects’ first language, the investi-
gator would assess their understanding of the process,
and make a decision on whether they could give
informed consent before entering them into the study.
Informed consent was obtained from each volunteer.
Chronic pain was defined as pain with intensity of at
least 5 on the 0-10 Numeric rate Scale (NRS) scale with
duration of at least 3 months. Diagnosis was based on
expert opinion and neuropathic features were addition-
ally confirmed by DN4 questionnaire (score equal or
higher than 4 out of 10) [18,19]. Because the study
aimed at assessing reproducibility, only patients on
stable medications were included. Subjects were advised
n o tt oh a v ea n yc o f f e i n eo ra l c o h o li nt h ee v e n i n gp r i o r
to each visit. NHVs where also asked not to take any
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as required analgesic, for 24 hours prior to each study
visit. Due to the nature of the transdermal device, any
subjects with skin problems, such as eczema or psoria-
sis, were excluded. Any subjects with a history of psy-
chosis or psychological disease which might affect
neural pathways, or hinder the patients pain perception
or ability to complete the task set out in this study, or
requiring psychoactive drug treatment were also
excluded.
Trans dermal stimulator
A recently described High Voltage Pain Stimulator (HV-
1) was used [20]. HV-1 produces trains of nanosecond-
range pulses with a train frequency of 2 Hz. Each train
consists of a variable number of single pulses. The
intensity of stimulation is defined as a number of pulses
in the train. The length of train varied between 0-6
milliseconds. Constant current or Pulse Width Modula-
tion (PWM) is impractical for nanosecond pulses in
kilovolt-range due to the limitation of available electro-
nic components. Electric pulses (similar to electrostatic
discharges) are transferred between the two electrodes
and skin by electrostatic discharges (Figure 1A). Single
electrostatic discharge has a biphasic dumped oscillating
characteristic with amplitude of 8000 Volts. The dis-
tance between the electrodes is equal to 8 mm and
there is 1 mm between each electrode and the skin (Fig-
ure 1B). There is no physical contact between the skin
and the electrodes. The stimulation head is attached to
the forearm by Velcro straps (Figure 1C).
Paradigm of electric stimulation
Electric stimulation was applied to the non-dominant
forearm via the High Voltage Pain Stimulator (HV-1).
At the beginning of each session the intensity of stimu-
lation (number of pulses in the train) was gradually
increased every 5 minutes over 15 minutes, targeting a
pain rating of five on the 11-point numeric rating scale
(NRS, 0 = No Pain, 10 = Maximum Imaginable Pain).
This was done in order to take into account individual
sensitivity to electrically evoked pain as this varies sub-
stantially across subjects. For the rest of the session (155
minutes for healthy volunteers and 75 minutes for
patients) the electric intensity was kept constant.
Throughout the stimulation the endpoints were mea-
sured every 5 minutes in the first 15 minutes and then
every 10 minutes once the electricity intensity was con-
stant. The paradigm of electric stimulation and mea-
surements is graphically presented at Table 1.
Endpoints
Four endpoints were measured:
1. Ongoing pain. Throughout the duration of experi-
ment subjects were asked to rate the pain sensation
Figure 1 Transdermal Electric Pain Stimulator (HV-1). A) Stimulator without enclosure. Electrostatic-like discharges are visible between skin
and the electrodes, B) Scheme of the stimulation head, C) Stimulator is simply attached to the forearm by Velcro strap.
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Scale (NRS 0-10, 0 = No Pain, 10 = Maximal Imaginable
Pain) and Visual Analogue Scale (VAS 0-100, 0 = No
Pain, 10 = Maximal Imaginable Pain). Due to subjective
character of pain intensity measurements two different,
independent pain scales was used for better validation.
2. Flare field. The size of the visual flare field was
measured as a diameter of skin redness. The skin was
observed, and diameter was measured in line parallel to
the axis of the forearm. The diameter was expressed in
centimeters.
3. Allodynic field. The size of the allodynic field was
measured as a diameter of brush evoked dynamic allo-
dynia to a response to foam brush stimulation. The skin
was gently brushed in two linear paths parallel to the
axis of the forearm from distant starting points towards
the stimulation site until the volunteer reported an
increase in sensation related to brushing. Volunteers
and patients reports this sensation as unpleasant (espe-
cially in proximity of stimulator. The diameter was
defined as the distance between the most proximal and
the most distal point at which volunteers’ reported an
increase in sensation, and was expressed in centimeters.
4. Hyperalgesic field. The size of the pin-prick punctu-
ate hyperalgesic field was measured as a diameter of
pin-prick punctuate hyperalgesia (Frey monofilament:
No 15, Force = 170 mN, Diameter = 0.61 mm, Pressure
=5 7 . 8g / m m
2, SenseLab - Aesthesiometer, Somedic,
Sweden and custom made weighted needle: Force = 200
mN, Diameter = 0.6 mm, Pressure = 70.78 g/mm
2). The
applied force was higher than the published mean
mechanical pain threshold (129 mN) on the hand in
NHVs [21]. There are no data available for pain thresh-
old on forearm and hand pain treshold was used as clo-
sest approximation available. The skin was stimulated by
a monofilament in two linear paths (proximal and distal)
parallel to the axis of the forearm from distant starting
points towards the stimulation site until the volunteer
reported an increase in sensation related to monofila-
ment stimulation. Volunteers and patients reports this
sensation as unpleasant (especially in proximity of sti-
mulator). Most subjects reports this sensation as painful.
The diameter was defined as the distance between the
most proximal and the most distal point at which volun-
teers report an increase of sensation and was expressed
in centimeters.
The fields of sensitization were estimated only in one
axis as preliminary data (not published) showed for
some subjects sensitizationo nd o r s a la r e ao ff o r e a r m
making measurements on axis perpendicular to forearm
very difficult.
Statistical methods
For each endpoint, pain scores, visual flare, allodynia
and hyperalgesia diameters, the average value over the
15 to 75 minutes-electrical stimulation period (area
under the curve divided by time, AUC/t) was calculated
and used as a summary measure; a mixed effect model
with subject as random effect, and visit as fixed effect
was fitted to each endpoint summary measure. Model
assumptions were checked by plotting residual plots.
The back-transformed ANOVA-adjusted means values
for each group of subjects were derived together with
the 95% confidence intervals based on the standard
error of the mean. From each model, the estimates of
intra-subject and inter-subject variances were obtained
to assess endpoint reproducibility. Analysis was com-
pleted using GenStat 8th edition http://www.vsn-intl.
com.
Results
Subjects
All data from the 16 male NHVs and the 16 patients
were included in the analyses. Data for the second visit
was missing for one NHV due to this subject moving to
another city and for two patients, one due to repetitive
non-compliancy with appointment times and the other
due to technical error for the other.
Tolerability
The stimulation was well tolerated by all subjects.
Despite no physical contact between the electrodes and
Table 1 Experimental protocol.
Time relative to
start of stimulation
0 5 10 15 25 35 45 55 65 75 85 95 105 115 125 135 145 155 165 175 185
Electrical
stimulation
↔
Stimulus titration x x x x
Measurements:
Pain score x x xxxxxxxxxx xxxxxxxxx
Punctatate
hyperalgesia
x xxxxxxxxxxx xxxxxxxxx
Brush
allodynia
x xxxxxxxxxxx xxxxxxxxx
This table shown time and events in both identical sessions
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but for most volunteers the injury was almost undetect-
able. One volunteer and two patients has obvious injury
bigger than 1 mm and less than 2 mm. All injuries
healed spontaneously in few days. Future studies could
include skin microphotography for formal injury
assessment.
Electrical current intensity
During the ramping-up period, the current intensity was
increased until reaching a pain score of 5 on the NRS
scale or until reaching the maximum current allowed, a
current intensity of 4 (Figure 2). Overall, patients
appeared to require a higher current intensity to reach a
pain score of 5 on the NRS scale; six out of the 16
patients (Subjects 1, 2, 4, 7, 8 and 9) reached the maxi-
mum current intensity on both visits for the continuous
electrical stimulation as compared to one NHV (Subject
4). Figure 2 also illustrates the visit-to-visit reproducibil-
ity of the current required to achieve a pain score of 5
on the NRS scale during the titration period. Current
values were very similar for both visits to the exception
of one subject in each group (healthy subject 11 and
chronic pain subject 5). Healthy subject 16 had to have
the current lowered from 25 min onwards on their first
visit because their pain reached a score of 6.
Pain scores
During the constant stimulation period, the intensity of
pain gradually decreased, despite the fact that the cur-
rent intensity remained constant, and after 75 minutes
of electrical stimulation the pain scores were on average
VAS ≥ 30 for NHVs and VAS ≥ 25 units for patients,
and NRS>3 units for NHVs and NRS~2.5 units for
patients. (see raw means plot on Figure 3). On stopping
the electrical stimulation, the pain disappeared instanta-
n e o u s l y( d a t an o ts h o w n ) .T h et i m ec o u r s eo ft h ep a i n
intensity appeared to be slightly different between the
two groups: the painful sensation seemed to decrease at
a faster rate in patients than in NHVs, and the average
pain over the 15-75 min period was lower in patients
(VAS, mean:30.6; adjusted s.e.:2.18 - NRS, mean:2.9; s.
e.:0.12) compared to the NHVs (VAS, mean:36.4; s.
e.:2.72 - NRS, mean:3.6; s.e.:0.19) (detailed in Table 2).
However, the 95% CI based on the standard error of the
means did overlap (Figure 3).
Visual flare diamete
We observed an area of flare visually (redness) in all
volunteers upon electrical stimulation. The diameter of
flare gradually increased, reaching a maximum at 50
minutes, and then gradually decreased independently of
the electrical stimulation to disappear by 100 minutes
post-stimulation (Figure 4 and data not shown). The
visit-to-visit reproducibility of the visual flare diameter
for each subject, as assessed by plotting individual time
courses, was good (data not shown). No difference was
observed in the mean visual flare over the 15-75 min
period or in the flare variability between NHVs
(mean:6.4; s.e.:0.50) and patients (mean:6.5; s.e.:0.53)
after adjustment for subject and visit effect (Table 2).
Figure 2 Individual time courses of electrical current intensity during the ramping-up period (0-15 min) by visit. Thick lines, Visit1;
dotted line, Visit2; a. Healthy volunteers; b. Patients.
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In the present study, one NHV did not experience
hyperalgesia and two patients experienced hyperalgesia
only to a limited extend. Interestingly, one of these
patients did experience a strong allodynic response,
whereas the other one did not experience any. Overall
the diameter of allodynia was within that of secondary
hyperalgesia.
Diameter static pin-prick hyperalgesia and dynamic
brush allodynia followed a similar time course, gradually
increasing and reaching their maxima in 35 minutes,
achieving an almost plateau effect (Figures 5 &6), then
gradually decaying during the post-stimulation period
(stimulator switched off, data not shown). The time
courses of these endpoints appeared to be similar for
the two groups of subjects studied.
From the raw mean plots, the ANOVA-adjusted
mean plots and the ANOVA model means and var-
iance components estimates, there did not seem to be
a n ye v i d e n c et h a tt h em e a na l l o d y n i cr e s p o n s eo v e r
the 15-75 min period, and the inter- and intra-subject
variabilities differed noticeably between NHVs
(mean:11.0; s.e.:0.74) and patients (mean: 10.1; s.
e.:0.74) (Figure 5 and Table 2).
Table 2 Summary table of mixed model ANOVA estimates.
HEALTHY VOLUNTEERS
ENDPOINTS Inter-subject SD Intra-subject SD ICC Mean Mean s.e. 95%CI lower 95%CI upper
Pain score (NRS) 1.0 0.8 0.5 3.6 0.19 3.17 3.93
Pain score (VAS) 12.5 10.9 0.2 36.4 2.72 31.07 41.73
Hyperalgesia diameter/195 mN Von Frey hair (cm) 5.6 1.9 0.9 13.9 0.47 13.02 14.84
Allodynia diameter/coton bud (cm) 5.8 2.9 0.7 11.0 0.74 9.59 12.47
Flare diameter (cm) 2.9 2.0 0.5 6.4 0.50 5.43 7.37
PATIENTS
ENDPOINTS Inter-subject SD Intra-subject SD ICC Mean Mean s.e. 95%CI lower 95%CI upper
Pain score (NRS) 1.0 0.5 0.8 2.9 0.12 2.63 3.09
Pain score (VAS) 14.6 8.7 0.6 30.6 2.18 26.33 34.87
Hyperalgesia diameter/195 mN Von Frey hair (cm) 5.9 2.0 0.9 9.9 0.49 8.91 10.85
Allodynia diameter/coton bud (cm) 6.6 3.0 0.8 10.1 0.74 8.66 11.58
Flare diameter (cm) 2.9 2.1 0.5 6.5 0.53 5.41 7.49
Figure 3 Average time course (0-75 min) of NRS (left panel) and VAS (right panel) pain scores at each visit.T h ee l e c t r i c a ls t i m u l a t i o n
was maintained for 155 minutes in HVs; and for 85 minutes in patients. Thick line, healthy volunteers; dotted lines, patients. Circles, Visit1;
Crosses, Visit2.
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Page 6 of 10Figure 4 Average time course (0-75 min) of visual flare diameter at each visit. Thick line, healthy volunteers; dotted lines, patients. Circles,
Visit1; Crosses, Visit2.
Figure 5 Average time course (0-75 min) of allodynia diameter at each visit. Thick line, healthy volunteers; dotted lines, patients. Circles,
Visit1; Crosses, Visit2.
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gesia data (Figure 6) suggested that the mean hyperalge-
sic response over the 15-75 min period was lower in
patients (mean:9.9; s.e.:0.49) when compared to NHVs
(mean:13.9; s.e.:0.47). The inter-subject and intra-subject
variabilities were quite similar for both study groups
(Table 2).
Discussion
Over the last decade, it has been recognized that the
traditional way of drug development (three phases) can
not be sustained and a new two phase has been sug-
gested. An exploratory phase where a proof of concept
is required followed by a full development program. A
validated model that can act as a surrogate marker,
would be a useful step in making the exploratory pro-
gram both efficient and meaningful [22]. The use of sur-
rogate markers to distinguish between pain mechanisms
may facilitate the conduct of clinical trials and the
development of new treatment strategies. Study groups
or subgroups that address pain mechanisms may be dis-
tinguished ad hoc by using surrogate endpoints, and
these may be used to evaluate patients’ responses to
treatment. Model to act as a surrogate marker, should
produce endpoints which are associated with and patho-
physiologically related to clinical outcome. A pain
model should be accurately validated through rigorous
reproducibility for each end point for it to be a potential
Biomarker.
Preclinical animal models have provided many crucial
insights in our understanding of pain mechanisms.
Nonetheless, their predictive value has increasingly
come to be questioned. In addition, relying totally on
NHVs models rather than patients’ models may lead to
similar questionable predictability as prompted by ani-
mal models.
These current studies have demonstrated that Trans-
dermal Electric Stimulation (TDES) can produce, robust
and highly reproducible data for ongoing pain, hyperal-
gesia and allodynia in NHVs and patients suffering
Figure 6 A v e r a g et i m ec o u r s e( 0 - 7 5m i n )o fh y peralgesia diameter at each visit. Thick line, healthy volunteers; dotted lines, patients.
Circles, Visit1; Crosses, Visit2.
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features. Transdermal Electric Stimulation (TDES) was
safe and well tolerated in both groups.
TDES has produced the features of central sensitiza-
tion that are associated with chronic neuropathic pain
syndrome. The spread of the pain and hypersensitivity
f r o mt h es i t eo fi n j u r y ,t h ea m p l i f i c a t i o ni ft h ep a i n
beyond the peripheral nerve distribution and the brush
evoked allodynia are all common manifestation of
chronic pain and now recognized as a result of central
sensitization [23].
Hyperalgesia was the most reproducible endpoint in
both NHV and patients in this study. Comparing the
data of hyperalgesia induced in patients and NHV, our
results seem to imply there isas i g n i f i c a n td i f f e r e n c e
between patients and NHVs in the size of hyperalgesia
field, being smaller in patients. This interesting observa-
tion may be explained either by the fact that the noci-
ceptive pathways in chronic pain patients have been
modified, so the response to a further stimulation is
reduced or by the chronic use of medications by
patients can alter the extent of further sensitization.
Group of patient was heterogeneous, not age-matched
to volunteers which could have confounding the results.
Allodynia was marginally less reproducible than
hyperalgesia. It was postulated that the mechanisms of
allodynia are distinct from the mechanisms of hyperal-
gesia[24]. In this model we observed a different time
trend for allodynia and hyperalgesia. Unlike for hyperal-
gesia, there did not seem to be any difference in allody-
nia field between patients and NHVs.
Ongoing pain was observed in both patients and
volunteers with some fading. Several theories have been
put forward for this phenomenon: depletion of neuro-
transmitters, habituation of nerve fibres, long-term
depression [25] and activation of descending inhibitory
pathways [13]. It is interesting to note that dynamics of
fade were different in NHVs and patients; this could
imply that chronic pain-modifying mechanisms are
involved in pain fading.
After the stimulator was switched off, pain disap-
peared immediately. In contrast, the field of sensitization
(hyperalgesia and allodynia) was observed to decay gra-
dually over a 30 minute period of post-stimulation.
Interestingly, the decay of sensitization after switching
off the stimulator was much slower in the patient group,
which further indicates the involvement of the central
sensitization processes (data was not shown).
Visual flare was very similar for both groups of sub-
jects. The production of a visible flare is believed to be
strictly due to peripheral mechanisms; therefore it was
not anticipated that a difference would be observed
between NHVs and patients with neuropathic pain who
are believed to suffer from an alteration occurring at the
CNS level.
Hyperalgesia and allodynia represent different features
of central sensitisation. It appears that in this model
particularly for patients rather than volunteers that the
mechanism involved may be totally separate. As the
result of that hyperalgesia differences appears between
patients and between volunteers where allodynia as the
separate pathway and a possible separate pathophysiolo-
gical mechanism appeared to be different. This is an
interesting finding from particularly this study, which
shows the importance of analysing hyperalgesia and allo-
dynia as separate and highlight potential differences
between patient and volunteers.
The multi modal nature of the response in this model
may make it ideal for use in the early phases of drug
development. Differences in time trends for pain, hyper-
algesia, allodynia and flare suggests that this pain model
would allow us to separately observe the mechanism
involved in the above processes. The study design was
to assess validity and reproducibility of TDES methodol-
o g y .S a m p l es i z ed a t an e e dt ob et a k e nw i t hc a u t i o nf o r
future drug evaluation studies for both: healthy volun-
teers and patients. Some pharmacological testing could
require assessment of reproducibility on repeated
administration of the same stimulus intensity. Table 2
included all data required by statistician to calculate
future study power for paradigm using the same subjec-
tive target pain intensity in the 2nd session.
Pain is not a reflex; it is a perceptual experience with
powerful emotional and motivational components. Like
all sensory systems, attributes of pain such as intensity,
quality, duration, location, and extension depend upon
cerebral processing. This applies to both laboratory ani-
mals and humans. Chronic pain necessarily results from
abnormal activity in pain transmission systems, perturb-
ing a hyperactive/hypersensitive pain pathway. Experi-
mental stimulation should have the potential to reveal
some differences that could improve our understanding
and facilitate new modalities for treatment [22].
Conclusion
Pain is one of the therapeutic areas of greatest clinical
need where there are few existing therapies and have
the least well-validated models or surrogate markers.
This is a first study which have tested the reproducibil-
ity and validity of transdermal electric stimulation pain
model in both normal healthy volunteers and patients
with neuropathic manifestation. This study has showed
a very good reproducible data both in volunteers and
patients with some subtle differences. The next option
for utilizing this model will be use it for pharmacologi-
cal drug development both for neuropathic and non-
neuropathic pain medications.
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